INCY Incyte Corp.

$INCY Latest analyst update, Oct 21, 2026: TD Cowen kept Buy and raised its price target on Incyte to 140 USD from 138 USD. Third-party analyst opinion. More details in our $INCY stock hub. Not investment advice.

$INCY: BUY alert went out Oct 5 after the close at $112.98. Sold Oct 15 at $114.86, +1.66% in 8 trading days. A boring, steady biotech worked better than the exciting names this month.

Latest company news, October 18, 2026: Incyte will present four rapid oral abstracts at ESMO 2026 (October 23-26) and hold an investor event on October 26, 2:30-4:00 p.m. ET. Incyte $INCY Stock Hub: Atebrioz Approval And The 2028 Cliff Deeper dive in our hub. Not investment advice.

$INCY: Incyte will show new data on KRAS G12D inhibitor INCB161734 and bispecific INCA33890 at ESMO 2026, with an investor event on Oct 26. Full breakdown in our hub.

$INCY Incyte slipped about 3.9% after hours on the Syndax IPF miss, and the scale here is just different. Axatilimab is Niktimvo in chronic GVHD, already approved, and it did 60.3 million dollars of net sales in Q2, up 67% YoY. That is roughly 4% of Incyte's 1.49 billion dollars in total Q2 net sales. IPF was expansion optionality on top of an approved product, not an existing revenue line, and the chronic GVHD studies are still running.

$INCY Mirum's Atebrioz approval was Friday's story. The other side of the deal is Incyte's, and it just repriced. Incyte developed zilurgisertib and licensed worldwide rights to Mirum in April: 16M upfront, up to 48M in regulatory milestones, up to 15M in commercial milestones, and mid-to-high single-digit tiered royalties on worldwide sales. Per reporting, 25M of those milestones was triggered by the approval itself. The part the headlines skipped: the FDA also handed Incyte a rare pediatric disease priority review voucher. Those are monetizable assets, sold for real money or used to speed a future filing. So Incyte outsourced FOP commercialization to Mirum's rare-disease infrastructure and kept milestone, royalty, and voucher claims. Mirum expects US availability in October; an EMA review is underway and decides how big the royalty base gets. H.C. Wainwright kept its Buy and raised the target to 152 from 150 on the approval.